RxDoctor Payments Data

Brian Munley, MD

Cardiovascular Disease · Asheboro, NCNPI 1093775793

Payments from drug & device makers

$7,114in general payments, 2019–2025

Across 394 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$751
  • Amgen$660
  • Merck$491
  • Johnson & Johnson$489
  • Sanofi-aventis U.S. LLC$485
  • Pfizer$471
  • plus $4K from 28 others

What the payments were for

  • Food & beverage$7,107100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,114 in reported general payments places this provider in the 65th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$60,391
Medicare patients
457
Services billed
1,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban836$849,912
EntrestoSacubitril/Valsartan248$276,943
Repatha SureclickEvolocumab253$207,457
XareltoRivaroxaban180$166,097
FarxigaDapagliflozin Propanediol138$133,384
NexletolBempedoic Acid60$44,465
Repatha SyringeEvolocumab39$30,347
MultaqDronedarone Hcl31$29,297
VerquvoVericiguat15$19,141
Praluent PenAlirocumab21$18,754
Ranolazine ErRanolazine118$10,598
Metoprolol Succinate665$8,924
NexlizetBempedoic Acid/Ezetimibe13$8,771
Torsemide272$7,141
Dabigatran EtexilateDabigatran Etexilate Mesylate18$6,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$471$849,912836 claims
NovartisEntresto$751$276,943248 claims
Johnson & JohnsonXarelto$489$166,097180 claims
AstraZenecaFarxiga$350$133,384138 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$438$53,23673 claims
Sanofi-aventis U.S. LLCMultaq$485$29,29731 claims
MerckVerquvo$491$19,14115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Asheboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →